Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All provided AI claims about composition and labeled indication are supported by the supplied FDA label excerpts. The approval date claim is not supported or verifiable from the provided excerpts.
Category Scores
Accurate Statements
Glyxambi is a combination medicine containing empagliflozin and linagliptin.
Section 1 INDICATIONS AND USAGE: "GLYXAMBI is a combination of empagliflozin and linagliptin..."
Glyxambi is used to improve blood sugar control in adults with type 2 diabetes.
Section 1 INDICATIONS AND USAGE: "GLYXAMBI ... indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."
Unsupported Statements
Glyxambi (empagliflozin/linagliptin) received FDA approval on September 12, 2015.
The supplied label excerpts do not include an FDA approval/approval date.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Unsupported approval-date information does not affect safe use. The supported indication and composition statements are consistent with the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Approval date claim not supported by the provided prescribing-information excerpts.
Suggested Improvement
Remove the approval-date statement or provide label-supported documentation for the approval date.